Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study

2017 ◽  
Vol 84 ◽  
pp. 34-43 ◽  
Author(s):  
A. de Nonneville ◽  
A. Gonçalves ◽  
C. Zemmour ◽  
M. Cohen ◽  
J.M. Classe ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adjuvant Chemotherapy ◽  
Triple Negative ◽  
Breast Carcinomas ◽  
Node Negative

scholarly journals Adjuvant chemotherapy in pT1ab node-negative triple negative breast carcinomas: Results of a national multi-institutional retrospective study

2017 ◽  
Vol 28 ◽  
pp. v52
Author(s):  
A. De Nonneville ◽  
A. Gonçalves ◽  
C. Zemmour ◽  
M. Cohen ◽  
J.M. Classe ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adjuvant Chemotherapy ◽  
Triple Negative ◽  
Breast Carcinomas ◽  
Node Negative

Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1092-1092 ◽  
Author(s):  
Priyanka Sharma ◽  
Bruce F. Kimler ◽  
Jennifer R. Klemp ◽  
Claire Ward ◽  
Carol Sue Connor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative

Adjuvant chemotherapy in small node-negative triple-negative breast cancer

2020 ◽  
Vol 135 ◽  
pp. 66-74
Author(s):  
Tessa G. Steenbruggen ◽  
Erik van Werkhoven ◽  
Mette S. van Ramshorst ◽  
Vincent O. Dezentjé ◽  
Marleen Kok ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative

scholarly journals PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease

2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Gloria Assaker ◽  
Anne Camirand ◽  
Bassam Abdulkarim ◽  
Atilla Omeroglu ◽  
Jean Deschenes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Factor ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Progression Free Survival ◽  
The Cancer Genome Atlas ◽  
Free Survival ◽  
Node Negative ◽  
Cancer Genome Atlas

Abstract Background Triple-negative breast cancer (TNBC) is characterized by poor prognosis and lack of targeted therapies and biomarkers to guide decisions on adjuvant chemotherapy. Parathyroid hormone-related protein (PTHrP) is frequently overexpressed in breast cancer and involved in proliferation and metastasis, two hallmarks of poor prognosis for node-negative breast cancer. We investigated the prognostic value of PTHrP with respect to organ-specific metastasis and nodal status in TNBC. Methods We assessed PTHrP expression using immunohistochemistry in a clinically annotated tissue microarray for a population-based study of 314 patients newly diagnosed with TNBC, then analyzed its correlation to progression and survival using Kaplan-Meier and Cox regression analyses. The Cancer Genome Atlas (TCGA) validation analysis was performed through Bioconductor. All statistical tests were two-sided. Results PTHrP overexpression (160 of 290 scorable cases, 55.2%) was statistically significantly associated in univariate analysis with decreased overall survival (OS) in our cohort (P = .0055) and The Cancer Genome Atlas (P = .0018) and decreased central nervous system (CNS)-progression-free survival (P = .0029). In multivariate analysis, PTHrP was a statistically significant independent prognostic factor for CNS-progression-free survival in TNBC (hazard ratio [HR] = 5.014, 95% confidence interval [CI] = 1.421 to 17.692, P = .0122) and for OS selectively in node-negative TNBC (HR = 2.423, 95% CI = 1.129 to 5.197, P = .0231). Strikingly, PTHrP emerged as the only statistically significant prognostic factor (HR = 2.576, 95% CI = 1.019 to 6.513, P = .0456) for OS of low-clinical risk node-negative patients who did not receive adjuvant chemotherapy. Conclusions PTHrP is a novel independent prognostic factor for CNS metastasis and adjuvant chemotherapy selection of low-clinical risk node-negative TNBC. Its predictive value needs to be prospectively assessed in clinical trials.

scholarly journals Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer

2022 ◽  
Author(s):  
Genevieve A. Fasano ◽  
Solange Bayard ◽  
Yalei Chen ◽  
Leticia Varella ◽  
Tessa Cigler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative

scholarly journals Benefit of Adjuvant Chemotherapy in Node-Negative T1a Versus T1b and T1c Triple Negative Breast Cancer

2021 ◽  
Author(s):  
Genevieve A Fasano ◽  
Solange Bayard ◽  
Yalei Chen ◽  
Leticia Varella ◽  
Tessa Cigler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Tumor Size ◽  
Triple Negative ◽  
The United States ◽  
Adjuvant Radiation ◽  
Node Negative ◽  
Cancer Network

Abstract Purpose: National Comprehensive Cancer Network guidelines recommend delivery of adjuvant chemotherapy in node-negative triple negative breast cancer (TNBC) if the tumor is > 1 cm and consideration of adjuvant chemotherapy for T1b but not T1a disease. These recommendations are based upon sparse data regarding the role of adjuvant chemotherapy in T1a and T1b node-negative TNBC. Our objective was to clarify the benefits of chemotherapy for patients with T1N0 TNBC, stratified by tumor size.Methods: We performed a retrospective analysis of survival outcomes in an IRB-approved prospectively-maintained database of TNBC patients treated at two academic institutions in the United States from 1999-2018. Primary tumor size, histology, and nodal status were based upon definitive surgical pathology. Mean follow-up was 5.3 years.Results: 756 TNBC cases were analyzed; 258 T1N0 TNBC patients were identified. Adjuvant chemotherapy was delivered to 30.5% of T1a, 64.7% T1b, and 83.9% T1c (p < 0.0001). Factors associated with delivery of adjuvant chemotherapy were age, histology, high-grade disease, and postoperative adjuvant radiation therapy. At a mean follow-up of 5.3 years, increase in overall survival was associated with use of chemotherapy in patients with T1c disease (93.2% v. 75.2% p = 0.008) but not in those with T1a (100% v. 100% p = 0.3778) or T1b (100% v. 95.8% p = 0.2362) disease.Conclusion: Our data support current guidelines indicating benefit from adjuvant chemotherapy in node-negative TNBC associated with T1c tumors but excellent outcomes were observed in cases of T1a and T1b disease, regardless of whether adjuvant chemotherapy was delivered.

Role of adjuvant chemotherapy in small (≤5 mm) node-negative and hormone receptor-negative breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12021-e12021
Author(s):  
Samip R. Master ◽  
Neelakanta Dadi ◽  
Chintan Shah ◽  
Gary Von Burton ◽  
Runhua Shi
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Hormone Receptor ◽  
Triple Negative ◽  
Outcome Variable ◽  
Node Negative ◽  
Risk Of Death ◽  
Node Negative Breast Cancer

e12021 Background: There is currently lack of adequate data to support for or against the role of adjuvant chemotherapy for small( < = 5mm) hormone negative and node negative breast cancer. We did a retrospective analysis from National Cancer Database (NCDB) to assess the effect of adjuvant chemotherapy in HER2 positive/ Hormone receptor negative (HER+HR-) and triple negative breast cancer. Methods: Data was analyzed from approximately nine thousand women registered in the (NCDB) who were diagnosed with triple negative and HER+ HR-small ( < = 5mm) and node negative breast cancer between 2010 and 2014 and had follow-up to the end of 2015. The primary predictor variable was the receipt of chemotherapy, and outcome variable was overall survival. Additional variables addressed and adjusted included age, race, Charlson Comorbidity Index and grade of cancer. Results: Approximately 59% patients received adjuvant chemotherapy. The five year overall survival in women with triple negative for breast cancer who received chemotherapy was 79% , compared to 87% , for those who did not receive chemotherapy(p < 0.00001). The five year overall survival in women with Her2+HR- for breast cancer who received chemotherapy was 68% , compared to 84% , for those who did not receive chemotherapy(p < 0.00001).In multivariate analysis, after adjusting for secondary predictor variables, avoidance of adjuvant chemotherapy was associated with 59.5% reduction in risk of death. Conclusions: Our analysis suggests that there are no role for adjuvant chemo in small breast cancers that are Her+ HR- and triple negative. The receipt of adjuvant chemotherapy lead to decrease in overall survival.

scholarly journals Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0140208
Author(s):  
SeungTaek Lim ◽  
Se Ho Park ◽  
Heong Kyu Park ◽  
Min Hee Hur ◽  
Se Jeong Oh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative ◽  
Korean Population ◽  
Prognostic Role ◽  
Node Negative ◽  
Medullary Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document